MRI screening may spot pancreatic cancer sooner in High-Risk gene carriers

NCT ID NCT05058846

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This pilot study is testing whether routine MRI scans can find early signs of pancreatic cancer in people who carry BRCA, ATM, or PALB2 gene mutations, which raise their risk. About 250 participants will undergo MRI, MRCP, endoscopic ultrasound, and provide blood, tissue, and saliva samples. The goal is to see how often these scans reveal abnormal findings and whether they can improve early detection and understanding of pancreatic cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Screening procedures including MRI, MRCP, endoscopic ultrasound, and biospecimen collection
What this could lead to
If successful, this could improve early detection of pancreatic cancer in high-risk individuals, potentially leading to better treatment outcomes.
What could go wrong
This is a pilot study, so results are preliminary. Screening may find abnormalities that are not cancer, leading to unnecessary procedures or anxiety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California San Francisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.